{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:38:31Z","timestamp":1794955111481,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Traditional Chinese Medicine Scientific Research Project","award":["2023004"],"award-info":[{"award-number":["2023004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    T-cell lymphoblastic leukemia\/lymphoma is a highly aggressive malignancy with a 5-year overall survival rate of 35%. Mutations in the JAK\/STAT pathway are the second most common mutations in T-cell lymphoblastic leukemia\/lymphoma, and hyperactivation of this pathway can promote proliferation of tumor cells. Considering that artesunate and ruxolitinib can inhibit activation of the JAK\/STAT pathway, this study investigated the value of these drugs in the treatment of T-lymphoblastic leukemia\/lymphoma. Jurkat cells were treated with various concentrations of artesunate and\/or ruxolitinib. Cell viability was detected using the CCK-8 assay, and apoptosis was detected after 48\u00a0h of treatment using flow cytometry. The effect of each drug alone and in combination was analyzed by polymerase chain reaction and western blotting assays. We also investigated the expression of relevant proteins in the JAK\/STAT pathway in lymph nodes and bone marrow samples from 10 patients with T-lymphoblastic leukemia\/lymphoma and two healthy controls. Artesunate and ruxolitinib, both alone and in combination, promoted apoptosis and reduced phosphorylation of JAK2 and STAT5 but did not alter mRNA or protein expression of JAK2. The drugs had a stronger inhibitory effect on growth when used in combination than when either was administered alone. Cytotoxicity assays indicated that artesunate had a potent inhibitory effect on cell viability, with IC\n                    <jats:sub>50<\/jats:sub>\n                    values of 12.86 (24\u00a0h) and 5.412 \u00b5M (48\u00a0h), whereas ruxolitinib had weaker activity (with an IC\n                    <jats:sub>50<\/jats:sub>\n                    of 30.55 \u00b5M at 24\u00a0h and 15.51 \u00b5M at 48\u00a0h). At 24\u00a0h, the total apoptotic rate was 20.75% in the control group, 30.00% in the 20 \u00b5M artesunate group, 27.24% in the 30 \u00b5M ruxolitinib group, and 43.39% in the combination group. Artesunate and ruxolitinib alone and in combination inhibited aberrant activation of the JAK\/STAT pathway in T-lymphoblastic lymphoma\/leukemia, supporting the value of this combination in patients with JAK\/STAT protein mutations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-39393-8","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:07:02Z","timestamp":1770815222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of artesunate and ruxolitinib suppresses T cell leukemia\/lymphoma proliferation via the JAK STAT pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Yupei","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"39393_CR1","doi-asserted-by":"publisher","unstructured":"Sergio, I. et al. Notch inhibitors and BH3 mimetics in T-Cell acute lymphoblastic leukemia. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms252312839 (2024).","DOI":"10.3390\/ijms252312839"},{"key":"39393_CR2","doi-asserted-by":"publisher","unstructured":"Gianni, F., Belver, L. & Ferrando, A. The genetics and mechanisms of T-Cell acute lymphoblastic leukemia. Cold Spring Harbor Perspect. Med. 10 https:\/\/doi.org\/10.1101\/cshperspect.a035246 (2020).","DOI":"10.1101\/cshperspect.a035246"},{"key":"39393_CR3","doi-asserted-by":"publisher","first-page":"2460252","DOI":"10.1080\/15384047.2025.2460252","volume":"& therapy26","author":"MA Al-Hamaly","year":"2025","unstructured":"Al-Hamaly, M. A., Winter, E. & Blackburn, J. S. The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia. Cancer Biology. & therapy26, 2460252. https:\/\/doi.org\/10.1080\/15384047.2025.2460252 (2025).","journal-title":"Cancer Biology"},{"key":"39393_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/s0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard, F. & Mohty, M. Acute lymphoblastic leukaemia. Lancet (London Engl. 395, 1146\u20131162. https:\/\/doi.org\/10.1016\/s0140-6736(19)33018-1 (2020).","journal-title":"Lancet (London Engl."},{"key":"39393_CR5","doi-asserted-by":"publisher","unstructured":"Shiraz, P., Jehangir, W. & Agrawal, V. T-Cell acute lymphoblastic Leukemia-Current concepts in molecular biology and management. Biomedicines 9 https:\/\/doi.org\/10.3390\/Biomedicines9111621 (2021).","DOI":"10.3390\/Biomedicines9111621"},{"key":"39393_CR6","doi-asserted-by":"publisher","unstructured":"Kuzilkov\u00e1, D. et al. Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of ex vivo treated pediatric T-cell acute lymphoblastic leukemia cells. Haematologica107, 1293\u20131310, (2022). https:\/\/doi.org\/10.3324\/haematol.2021.278796","DOI":"10.3324\/haematol.2021.278796"},{"key":"39393_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-024-03199-1","volume":"43","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors. j. Exp. Clin. Cancer Res. 43, 283. https:\/\/doi.org\/10.1186\/s13046-024-03199-1 (2024).","journal-title":"j. Exp. Clin. Cancer Res."},{"key":"39393_CR8","doi-asserted-by":"publisher","unstructured":"Lahera, A. et al. PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK\/STAT pathway mutations in T-ALL\/LBL. Npj Precision Oncol. 8 (152). https:\/\/doi.org\/10.1038\/s41698-024-00638-2 (2024).","DOI":"10.1038\/s41698-024-00638-2"},{"key":"39393_CR9","doi-asserted-by":"publisher","unstructured":"Kashyap, A., Dai, J. & Ni, X. Therapeutic targeting of the Janus Kinase\/Signal transducer and activator of transcription pathway in cutaneous T- cell lymphoma. Cancers (Basel. 17 https:\/\/doi.org\/10.3390\/cancers17040568 (2025).","DOI":"10.3390\/cancers17040568"},{"key":"39393_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell Jr","year":"1997","unstructured":"Darnell, J. E. Jr. STATs and gene regulation. Science 277, 1630\u20131635. https:\/\/doi.org\/10.1126\/Science.277.5332.1630 (1997).","journal-title":"Science"},{"key":"39393_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/ijo.18.4.767","volume":"18","author":"T Efferth","year":"2001","unstructured":"Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. & Chitambar, C. R. The anti-malarial ART is also active against cancer. Int. J. Oncol. 18, 767\u2013773. https:\/\/doi.org\/10.3892\/ijo.18.4.767 (2001).","journal-title":"Int. J. Oncol."},{"key":"39393_CR12","doi-asserted-by":"publisher","first-page":"2255802","DOI":"10.1080\/16078454.2023.2255802","volume":"28","author":"Q Su","year":"2023","unstructured":"Su, Q. et al. ART reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK\/STAT3 signaling. Hematol. (Amsterdam Neth. 28, 2255802. https:\/\/doi.org\/10.1080\/16078454.2023.2255802 (2023).","journal-title":"Hematol. (Amsterdam Neth."},{"key":"39393_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.7150\/ijms.86409","volume":"20","author":"L Liang","year":"2023","unstructured":"Liang, L., Liu, Y., Wu, X. & Chen, Y. ART induces ferroptosis by inhibiting the nuclear localization of SREBP2 in myeloma cells. Int. J. Med. Sci. 20, 1535\u20131550. https:\/\/doi.org\/10.7150\/ijms.86409 (2023).","journal-title":"Int. J. Med. Sci."},{"key":"39393_CR14","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/j.clml.2024.12.013","volume":"25","author":"HK Al-Ali","year":"2025","unstructured":"Al-Ali, H. K., Gerds, A. T., Grunwald, M. R. & Yu, J. A. Review of Real-World experience with RUX for myelofibrosis. Clin. Lymphoma Myeloma Leuk. 25, e262\u2013e281. https:\/\/doi.org\/10.1016\/j.clml.2024.12.013 (2025).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"39393_CR15","doi-asserted-by":"publisher","unstructured":"Ye, Y. et al. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. Exp. Hematol. Oncol. 10 https:\/\/doi.org\/10.1186\/s40164-021-00200-x (2021).","DOI":"10.1186\/s40164-021-00200-x"},{"key":"39393_CR16","doi-asserted-by":"publisher","first-page":"13976","DOI":"10.1074\/jbc.271.24.13976","volume":"271","author":"JW Verbsky","year":"1996","unstructured":"Verbsky, J. W. et al. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J. Biol. Chem. 271, 13976\u201313980. https:\/\/doi.org\/10.1074\/jbc.271.24.13976 (1996).","journal-title":"J. Biol. Chem."},{"key":"39393_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0014-5793(94)80485-0","volume":"342","author":"T Takahashi","year":"1994","unstructured":"Takahashi, T. & Shirasawa, T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett. 342, 124\u2013128. https:\/\/doi.org\/10.1016\/0014-5793(94)80485-0 (1994).","journal-title":"FEBS Lett."},{"key":"39393_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott, L. M. The JAK2 exon 12 mutations: a comprehensive review. Am. J. Hematol. 86, 668\u2013676. https:\/\/doi.org\/10.1002\/ajh.22063 (2011).","journal-title":"Am. J. Hematol."},{"key":"39393_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 9, 798\u2013809. https:\/\/doi.org\/10.1038\/nrc2734 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"39393_CR20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"M Kiel","year":"2014","unstructured":"Kiel, M. et al. (ed, J.) Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124 1460\u20131472 https:\/\/doi.org\/10.1182\/Blood-2014-03-559542 (2014).","journal-title":"Blood"},{"key":"39393_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","volume":"489","author":"P Koppikar","year":"2012","unstructured":"Koppikar, P. et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155\u2013159. https:\/\/doi.org\/10.1038\/Nature11303 (2012).","journal-title":"Nature"},{"key":"39393_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3760\/cma.j.cn121090-20240412-00138","volume":"45","author":"PP Xu","year":"2024","unstructured":"Xu, P. P. et al. [RUX combined with venetoclax and Azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 45, 872\u2013875. https:\/\/doi.org\/10.3760\/cma.j.cn121090-20240412-00138 (2024).","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"39393_CR23","doi-asserted-by":"publisher","unstructured":"Moskowitz, A. J. et al. Final Results of a Phase II Biomarker-Driven Study of RUX in Relapsed and Refractory T-Cell Lymphoma. Blood134, 4019\u20134019,. (2019). https:\/\/doi.org\/10.1182\/blood-2019-125017","DOI":"10.1182\/blood-2019-125017"},{"key":"39393_CR24","doi-asserted-by":"publisher","unstructured":"Kim, C., Lee, J. H., Kim, S. H., Sethi, G. & Ahn, K. S. ART suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model. Oncotarget6, 4020\u20134035, (2015). https:\/\/doi.org\/10.18632\/oncotarget.3004","DOI":"10.18632\/oncotarget.3004"},{"key":"39393_CR25","doi-asserted-by":"publisher","unstructured":"Jochims, F. et al. The antimalarial drug ART mediates selective cytotoxicity by upregulating HO-1 in melanoma cells. Biomedicines 11 https:\/\/doi.org\/10.3390\/Biomedicines11092393 (2023).","DOI":"10.3390\/Biomedicines11092393"},{"key":"39393_CR26","doi-asserted-by":"publisher","first-page":"107526","DOI":"10.1016\/j.phrs.2024.107526","volume":"210","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. ART: a potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma. Pharmacol. Res. 210, 107526. https:\/\/doi.org\/10.1016\/j.phrs.2024.107526 (2024).","journal-title":"Pharmacol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39393-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:40:59Z","timestamp":1772800859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39393-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7241143\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8354"}}